Dana Investment Advisors Inc. Decreases Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Dana Investment Advisors Inc. reduced its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 4.5% in the second quarter, Holdings Channel reports. The institutional investor owned 102,499 shares of the biotechnology company’s stock after selling 4,840 shares during the period. Dana Investment Advisors Inc.’s holdings in Aurinia Pharmaceuticals were worth $1,328,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the business. Lindbrook Capital LLC increased its stake in shares of Aurinia Pharmaceuticals by 33.3% in the second quarter. Lindbrook Capital LLC now owns 4,000 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 1,000 shares in the last quarter. Sowell Financial Services LLC increased its stake in shares of Aurinia Pharmaceuticals by 72.6% in the first quarter. Sowell Financial Services LLC now owns 2,512 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 1,057 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 1.1% in the first quarter. Geode Capital Management LLC now owns 127,875 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 1,376 shares in the last quarter. Accel Wealth Management increased its stake in shares of Aurinia Pharmaceuticals by 309.3% in the second quarter. Accel Wealth Management now owns 1,985 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 1,500 shares in the last quarter. Finally, CIBC World Markets Inc. increased its stake in shares of Aurinia Pharmaceuticals by 11.9% in the first quarter. CIBC World Markets Inc. now owns 14,131 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 1,507 shares in the last quarter. 38.27% of the stock is owned by institutional investors and hedge funds.

AUPH stock opened at $21.50 on Wednesday. Aurinia Pharmaceuticals Inc. has a 52 week low of $9.72 and a 52 week high of $21.86. The company has a fifty day simple moving average of $14.59 and a two-hundred day simple moving average of $13.50. The firm has a market capitalization of $2.76 billion, a P/E ratio of -19.55 and a beta of 0.48.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 242.26% and a negative return on equity of 36.98%. The business had revenue of $6.62 million for the quarter, compared to the consensus estimate of $4.98 million. Research analysts anticipate that Aurinia Pharmaceuticals Inc. will post -1.34 EPS for the current fiscal year.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 17th. SVB Leerink restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 19th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $27.33.

In other news, insider Michael Robert Martin sold 5,000 shares of the stock in a transaction on Wednesday, July 28th. The shares were sold at an average price of $13.86, for a total value of $69,300.00. Following the sale, the insider now owns 211,861 shares of the company’s stock, valued at $2,936,393.46. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Robert Bindert Huizinga sold 10,000 shares of the stock in a transaction on Friday, September 10th. The shares were sold at an average price of $19.80, for a total transaction of $198,000.00. Following the completion of the sale, the executive vice president now directly owns 133,592 shares in the company, valued at approximately $2,645,121.60. The disclosure for this sale can be found here. Insiders have sold 167,500 shares of company stock valued at $3,386,875 in the last quarter. 3.10% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

See Also: Stock Portfolio Tracker

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.